Black checkmark with a sparkle and a curved line underneath on a white background.
Company

iSpecimen Inc.

Ticker
ISPC
Sector
Industry
Report date
November 17, 2026
Valye AI Score

86

Very high visibility
Recent developments
Recent developments summary

Recent developments include multiple private placements to support marketplace expansion, operational improvements such as reduced shipping times, and strategic initiatives to strengthen leadership and expand cancer research focus.

Recent developments:
  • iSpecimen announced a $400,000 private placement of Series D convertible preferred stock in November 2026 [N1].
  • The company completed an international cancer research order in August 2026 [N3].
  • In May 2026, iSpecimen announced and priced a $2.5 million private placement to support marketplace expansion [N4][N5].
  • Operational improvements include cutting shipping times by 85%, leading to positive market reactions in April 2026 [N6].
  • iSpecimen strengthened leadership and expanded its cancer research focus as of April 2026 [N7].
  • The company rallied on biospecimen marketplace expansion initiatives in March 2026 [N8].
  • Revenue declined approximately 71% for the nine months ended September 30, 2026, while sales and marketing expenses increased by about 99%, contributing to management's substantial doubt about going concern status [S2].
Overview

iSpecimen Inc. is a technology-driven company focused on transforming the biospecimen procurement market through its iSpecimen Marketplace platform. The platform connects life science researchers with healthcare providers who supply human biospecimens and associated data, consolidating a fragmented and inefficient market into a single online marketplace. The platform ingests and harmonizes de-identified healthcare data from electronic medical records and other sources, enabling researchers to search for specimens that meet specific study criteria and manage the procurement workflow from inquiry to invoice. The company shares revenue with specimen suppliers and provides marketing, sales, contracting, and compliance services as part of the procurement process. Recent technology investments include migrating to a cloud-native platform built on SalesStack to improve scalability, security, and operational integration. As of late 2025, the platform included data on approximately 19 million patients and over 105 million clinical specimens. The company has delivered over 218,000 specimens across more than 3,500 projects since inception. iSpecimen has also expanded its focus on cancer research and enhanced leadership to support growth initiatives.

Executive summary

iSpecimen Inc. operates a technology-driven biospecimen marketplace platform that connects life science researchers with healthcare providers to facilitate the procurement of human biospecimens and associated data. The platform integrates data from millions of patient records and specimen inventories, enabling researchers to efficiently search, select, and order specimens through an end-to-end workflow. The company generates revenue by procuring specimens from providers and distributing them to researchers, sharing revenue with suppliers. Recent financial disclosures show revenue of $244,034 and a net loss of $2.21 million for the nine months ended September 30, 2026, with liquidity ratios indicating a current ratio of 1.16 and a cash ratio of 2.15 as of that date. iSpecimen has undertaken multiple private placements in 2026 to support marketplace expansion and operations. Management has disclosed substantial doubt about the company's ability to continue as a going concern due to revenue decline and increased expenses. The company continues to invest in technology modernization and operational improvements to enhance platform scalability and user experience. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for ISPC

Bull case model:

The company has demonstrated progress in modernizing its technology platform to a cloud-native architecture, which may enhance scalability, security, and operational efficiency. Recent private placements provide capital to support marketplace expansion and operational initiatives. Operational improvements such as significantly reduced shipping times and expanded cancer research focus indicate active efforts to improve customer experience and market relevance. The large and growing dataset of patient and specimen records supports the platform's value proposition to researchers and suppliers. Continued enhancements to the platform's search, workflow, and data integration capabilities could strengthen its position as a leading biospecimen marketplace.

Bear case model:

The company faces challenges including a significant revenue decline of approximately 71% for the nine months ended September 30, 2026, and a net loss impacting financial sustainability. Management has expressed substantial doubt about the company's ability to continue as a going concern. Increased sales and marketing expenses have not yet translated into revenue growth. The biospecimen procurement market remains fragmented and complex, requiring ongoing investment to scale the platform and expand supplier and researcher engagement. Execution risks include the ability to successfully integrate and leverage data, maintain compliance, and achieve operational efficiencies necessary for sustainable growth.

Moat:

iSpecimen's moat is anchored in its proprietary technology platform that integrates a large and diverse network of healthcare providers and researchers, enabling efficient biospecimen procurement through a unified marketplace. The company's ability to ingest, harmonize, and manage vast amounts of de-identified healthcare data from multiple sources creates a significant data asset that supports effective specimen matching and procurement workflows. The platform's end-to-end workflow orchestration, compliance management, and revenue-sharing arrangements with suppliers foster strong network effects and supplier engagement. Additionally, the company's investments in modernizing its technology infrastructure and expanding operational capabilities contribute to its competitive positioning in a fragmented and complex market.

Risks overview
Risks summary
The most significant risk is the company's financial sustainability given recent revenue declines, net losses, and management's expressed doubt about continuing as a going concern.
Risks details:

• Financial Sustainability Risk: The company reported a significant revenue decline and net losses, with management expressing substantial doubt about its ability to continue as a going concern, indicating financial sustainability challenges.
• Market Fragmentation and Complexity: The biospecimen procurement market is highly fragmented and complex, requiring continuous investment in technology and supplier engagement to maintain and grow the marketplace.
• Execution and Integration Risk: Successful integration of large and diverse healthcare data sets and ongoing platform modernization are critical to operational efficiency and customer satisfaction, posing execution risks.
• Regulatory and Compliance Risk: The company must maintain strict compliance with healthcare data privacy regulations and supplier protocols, which requires robust administrative and compliance management systems.

FINAL FORECAST FOR ISPC

Final take one line
iSpecimen operates a technology-driven biospecimen marketplace with detailed disclosures and recent capital raises but faces financial sustainability challenges amid revenue decline.
Final take 12 to 24 month view

Business trends: Continued investment in technology modernization and marketplace expansion with focus on cancer research and operational improvements.
Execution milestones: Completion of platform migration to cloud-native architecture, multiple private placements to support growth, and operational efficiency gains such as reduced shipping times.
Key risks: Financial sustainability concerns due to revenue decline and net losses, market fragmentation requiring ongoing investment, execution risks in data integration and platform scaling, and regulatory compliance demands.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

86
LLM visibility overview
LLM Visibility known facts
  • iSpecimen Inc. operates a technology-driven biospecimen marketplace platform connecting life science researchers with healthcare providers supplying human biospecimens and associated data [S1].
  • The iSpecimen Marketplace consolidates biospecimen procurement into a single online platform, enabling researchers to search, select, and order specimens with associated data from a diverse network of providers [S1].
  • The platform ingests and harmonizes de-identified healthcare data from electronic medical records and other sources, covering approximately 19 million patient records and over 105 million clinical specimen records as of December 31, 2025 [S1].
  • The marketplace supports end-to-end workflows including specimen search, ordering, fulfillment, and compliance management for both researchers and suppliers [S1].
  • Revenue is generated by procuring specimens from healthcare providers and distributing them to researchers, with revenue sharing arrangements typically ranging from 20% to 50% back to suppliers [S1].
  • The company has modernized its technology platform with a cloud-native architecture built on SalesStack, improving scalability, security, and operational integration [S1].
  • As of September 30, 2026, iSpecimen reported cash and cash equivalents of $5.56 million and current liabilities of approximately $5.47 million, with a current ratio of 1.16 and a cash ratio of 2.15 [S2].
  • For the nine months ended September 30, 2026, revenue was $244,034 with a net loss of $2.21 million and basic and diluted EPS of -$1.03 [S2].
  • The company completed multiple private placements in 2026, including a $2.5 million placement in May and a $400,000 Series D convertible preferred stock placement in November to support marketplace expansion and operations [N1][N4][N5].
  • iSpecimen has focused on expanding its cancer research focus and strengthening leadership as part of its strategic initiatives [N7].
  • The company has achieved operational improvements such as cutting shipping times by 85%, enhancing customer experience and supplier engagement [N6][N8].
  • Management has disclosed substantial doubt about the company's ability to continue as a going concern, citing revenue decline and increased sales and marketing expenses [S2].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-01 | 10-K
  • S2 | 2026-11-17 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | iSpecimen Inc. Announces $400,000 Private Placement of Series D Convertible Preferred Stock | https://www.nasdaq.com/articles/ispecimen-inc-announces-400000-private-placement-series-d-convertible-preferred-stock
  • N2 | 2026-09-08 | www.nasdaq.com | ISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA Decision | https://www.nasdaq.com/articles/ispecimen-focus-genelux-nears-phase-3-ovarian-cancer-data-biofrontera-awaits-fda-decision
  • N3 | 2026-08-21 | www.nasdaq.com | ISpecimen Completes International Cancer Research Order; Stock Down | https://www.nasdaq.com/articles/ispecimen-completes-international-cancer-research-order-stock-down
  • N4 | 2026-05-11 | www.nasdaq.com | ISpecimen Announces Private Placement Worth $2.5 Mln | https://www.nasdaq.com/articles/ispecimen-announces-private-placement-worth-25-mln
  • N5 | 2026-05-11 | www.nasdaq.com | ISpecimen Prices $2.5Mln Private Placement To Support Marketplace Expansion | https://www.nasdaq.com/articles/ispecimen-prices-25mln-private-placement-support-marketplace-expansion
  • N6 | 2026-04-10 | www.nasdaq.com | ISpecimen Cuts Shipping Times By 85%, Shares Surge | https://www.nasdaq.com/articles/ispecimen-cuts-shipping-times-85-shares-surge
  • N7 | 2026-04-01 | www.nasdaq.com | iSpecimen Strengthens Leadership and Expands Cancer Research Focus | https://www.nasdaq.com/articles/ispecimen-strengthens-leadership-and-expands-cancer-research-focus
  • N8 | 2026-03-13 | www.nasdaq.com | ISpecimen Rallies On Biospecimen Marketplace Expansion | https://www.nasdaq.com/articles/ispecimen-rallies-biospecimen-marketplace-expansion
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine